Acquires Two State-of-the-Art Facilities and Packaging Capabilities for “Turnkey” Solutions
Catalent, Inc. (Catalent) (NYSE:CTLT), the leading global provider of
advanced delivery technologies and development solutions for drugs,
biologics and consumer health products, today announced that it has
agreed to acquire Accucaps Industries Limited (Accucaps), the
Canada-based developer and manufacturer of Over-the-Counter (OTC), high
potency and conventional pharmaceutical softgels. Financial details of
the transaction have not been disclosed.
The acquisition, which is subject to Canadian governmental approval,
will substantially complement Catalent’s global OTC and prescription
pharmaceutical softgel capabilities and capacity with the addition of a
portfolio of products supplied to pharmaceutical companies in North
America, and two state-of-the-art facilities offering integrated softgel
development, manufacturing and packaging, strengthening Catalent’s
ability to offer customers turnkey solutions.
Commenting on the acquisition, Dr. Aris Gennadios, Catalent’s President
of Softgel Technologies, said, “Significant investments already made
by Accucaps align well with Catalent’s own strategic goals, to offer our
customers access to more products, capacity, and integrated solutions
for differentiated products and better treatments.”
Upon completion of the acquisition, Accucaps’ over 500 employees, at its
two facilities in Windsor and Strathroy, Ontario, will join Catalent’s
global network of 11 Softgel Technologies facilities. The Accucaps
facilities house sizeable blistering, bottling and other packaging
capabilities, as well as high-potency prescription softgel development
and manufacturing expertise that are complementary to Catalent’s.
Catalent RP Scherer Softgel is a global leader in innovative oral and
topical softgel technologies for the pharmaceutical, consumer health,
and cosmetics markets. Its softgel technologies are proven to solve
complex bioavailability and formulation challenges, and are preferred in
a wide range of consumer health and pharmaceutical product categories.
Catalent leverages more than 80 years of experience in softgel
formulation, development and manufacturing, as well as its proactively
developed products, to help customers bring products to market faster.
With a variety of unique, innovative technologies, and highly versatile,
most preferred dose forms, Catalent has a wide variety of solutions to
meet its customers’ needs.
Catalent was advised by RBC Capital Markets.
Notes for Editors
About Catalent, Inc.
Catalent, Inc. (NYSE:CTLT), is the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products. With over 80 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs over 9,500
people, including over 1,400 scientists, at more than 30 facilities
across five continents, and in fiscal 2016 generated $1.85 billion in
annual revenue. Catalent is headquartered in Somerset, New Jersey. For
more information, visit www.catalent.com
More products. Better treatments. Reliably supplied.™
Forward-Looking Statements
This release contains both historical and forward-looking statements.
All statements other than statements of historical fact are, or may be
deemed to be, forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. For example, statements
that describe the Company’s objectives, plans or goals are, or may be,
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results
could vary materially from Catalent’s expectations and projections. Some
of the factors that could cause actual results to differ include, but
are not limited to, the following: whether Catalent can complete the
acquisition of Accucaps as anticipated; unanticipated difficulties in
integrating Accucaps into the Catalent network; unanticipated negative
reactions from customers or other business partners of Accucaps;
participation in a highly competitive market and increased competition
that may adversely affect the businesses of Catalent or Accucaps; demand
for Catalent’s or Accucaps’ offerings, which depends in part on the
respective customers’ research and development and the clinical and
market success of their products; product and other liability risks that
could adversely affect Catalent’s or Accucaps’ results of operations,
financial condition, liquidity and cash flows; failure to comply with
existing and future regulatory requirements; failure to provide quality
offerings to customers that could have an adverse effect on Catalent’s
or Accucaps’ business and subject either company to regulatory actions
or costly litigation; problems providing the highly exacting and complex
services or support required; global economic, political and regulatory
risks that may adversely affect the operations of Catalent or Accucaps;
inability to enhance existing or introduce new technology or service
offerings in a timely manner; inadequate protection from patents,
copyrights, trademarks and other forms of intellectual property;
fluctuations in the costs, availability, and suitability of the
components of the products Catalent and Accucaps manufacture, including
active pharmaceutical ingredients, excipients, purchased components and
raw materials; changes in market access or healthcare reimbursement in
the United States or internationally; fluctuations in the exchange rate
of the U.S. dollar, the Canadian dollar, and other foreign currencies;
adverse tax legislation, initiatives or challenges to Catalent’s or
Accucaps’ tax positions; loss of key personnel; risks generally
associated with information systems; inability to complete any future
acquisitions or other transactions that may complement or expand the
business of Catalent or divest non-strategic businesses or assets and
Catalent’s ability to successfully integrate acquired businesses and
realize anticipated benefits of such acquisitions; offerings and
customers’ products that may infringe on the intellectual property
rights of third parties; environmental, health and safety laws and
regulations, which could increase costs and restrict operations; risks
arising from complex and shifting labor and employment laws and
regulations; risks associated with raising and paying additional cash
contributions required to fund existing pension or other retirement
obligations; and substantial leverage resulting in the limited ability
of Catalent to raise additional capital to fund operations and react to
changes in the economy or in the industry. For a more detailed
discussion of these and other factors, see the information under the
caption “Risk Factors” in the Company’s Annual Report on Form 10-K for
the fiscal year ended June 30, 2016, filed with the United States
Securities and Exchange Commission. All forward-looking statements speak
only as of the date of this release or as of the date they are made, and
Catalent does not undertake to update any forward-looking statement as a
result of new information or future events or developments except to the
extent required by law.
Catalent, Inc.
Chris Halling, +44 (0)7580 041073
[email protected]
or
Richard Kerns, +44 (0) 161 728 5880
[email protected]
or
Investors:
Thomas Castellano, +1 (732) 537-6325
[email protected]